Clinical trials: Movement Abnormalities
Parkinson Disease
CS1P1 PET Studies of Neuroinflammation in Parkinson Disease
Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking.
- Trial name
- NCT06084533
- Testing
- [11C]-CS1P1
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Parkinson Disease, MSA - Multiple System Atrophy
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Lewy Body Dementia (LBD), Neurodegenerative Disease
- Trial name
- EXTRAORDINARY (NCT06846658)
- Where
- 3 sites in Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Parkinson Disease, Parkinsonism
Events Exposure as a Trigger of the Clinical Manifestations of Parkinson's Disease
Stress has been implicated as a trigger of many diseases, throughout different mechanisms. Potentially traumatic/stressful events exposure might be a factor that triggers subclinical disabilities related to PD becoming evident to…
- Trial name
- NCT05308485
- Testing
- Events exposure questionnaire
- Where
- Argentina
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
Huntington's Disease (HD)
Biology-Driven Cognitive Profiling in Huntington's Disease
Huntington's disease (HD) is a genetic, progressive neurodegenerative disorder characterized by early and widespread brain changes that can begin more than a decade before the onset of unequivocal motor signs.
- Trial name
- NCT07503743
- Where
- Spain
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Dementia With Lewy Bodies, Alzheimer Disease
Optical Neuroimaging and Cognition
Dementia is associated with a variety of neurovascular and neurometabolic abnormalities. Traditional imaging techniques used to investigate such abnormalities, such as Positron Emission Tomography and functional Magnetic…
- Conditions
- Dementia With Lewy Bodies, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- ONAC (NCT05460143)
- Testing
- Near-infrared Spectroscopy scan, Magnetic Resonance Imaging scan
- Where
- United Kingdom
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
Parkinson Disease
EEG Recordings and Analysis in Parkinson's Patients: Towards Adaptive Deep Brain Stimulation by Machine Learning
The objective of this protocol is to obtain on Parkinson's disease more accessible therapeutic targets than deep brain stimulation (HFS-STN), the neurosurgical treatment for this pathology.
- Trial name
- ElectroPARK (NCT05284526)
- Testing
- electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Parkinson Disease, Mood
The Benefits of Nature for Mood and Cognition in Persons With and Without Parkinson's Disease
This online study aims to explore the benefits of nature for mood and cognition in persons with and without Parkinson's disease.
- Conditions
- Parkinson Disease, Mood, Cognition
- Trial name
- NCT06483126
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Hallux Limitus, Movement, Abnormal
Foot Posture Index, Hallux Limitus in Patients With Chronic Low Back Pain. Gait With Optogait Sensor
Foot disorders have been recognized as being linked to chronic low back pain
- Conditions
- Hallux Limitus, Movement, Abnormal, Back Pain Lower Back Chronic
- Trial name
- NCT04607863
- Testing
- Case control
- Where
- Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Seville
Huntington Disease
Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease
This study will investigate if a new experimental drug to treat Huntington's Disease gets into the brain. If it does get into the brain the study will explore the relationship between the amount of drug in the brain and the…
- Trial name
- NCT01602900
- Testing
- GSK356278, Rolipram
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers (HV), Parkinson's Disease (PD)
Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease
This is a first-in-human (FIH) study of orally administered VT-5006 (also known as AX-5006) in healthy adult volunteers (HVs) and adult participants with Parkinson's disease (PD).
- Trial name
- NCT07310264
- Testing
- VT-5006
- Where
- Netherlands
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Vertero Therapeutics
PARKINSON DISEASE (Disorder)
Stanford University Neurofiber Study
Parkinson's disease often causes constipation and changes in gut bacteria, but it is not known how quickly a daily fiber supplement changes gut physiology in people with Parkinson's, or how long any change lasts after stopping.
- Trial name
- SUNs (NCT07914387)
- Testing
- Prebiotic fiber bar
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Stanford University
Multisystemic Atrophy
Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study
Background: Multiple System Atrophy (MSA) is an atypical parkinsonian syndrome including cerebellar impairment and poor response to dopatherapy.
- Trial name
- MSAJOY (NCT01044992)
- Testing
- H215O PET, Levodopa
- Where
- 4 sites in France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Huntington Disease
Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease
Huntington disease (HD, 1.3/10 000) is an autosomal dominant disease due to an abnormal expansion of CAG triplets in HTT gene. Several pathophysiological mechanisms have been evoked, including an alteration of the signaling…
- Trial name
- LCR-MH (NCT04012411)
- Testing
- Brain MRI, Lumbar Punction, Blood sample
- Where
- France
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Parkinson Disease, Dementia
Imaging Studies of Cognitive Impairment in Parkinson s Disease
Background: Parkinson's disease causes slow movements, stiffness, and tremor. It can get worse over time, and in some cases can lead to dementia.
- Trial name
- NCT01862744
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson Disease, Tremor
Action Observation Therapy and Mirror Therapy in Parkinson's Disease
Small muscles of the hand are affected due to involuntary movements and slowing of voluntary movements seen in Parkinson's disease. There is a loss of fine dexterity and coordination in the hand.
- Trial name
- NCT05350709
- Testing
- mirror therapy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Kirsehir Ahi Evran Universitesi
Huntington's Disease
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
The pace of basic science research defining the mechanisms of selective neuronal degeneration in Huntington disease (HD) has far exceeded the pace of translation of this information into clinically effective treatments for the…
- Trial name
- HD (NCT00670709)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration
PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Progressive Supranuclear Palsy (PSP), Cortico-Basal Degeneration (CBD) and Multiple System Atrophy (MSA) are degenerative brain conditions for which there are currently no curative treatments.
- Conditions
- Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration, Multiple System Atrophy (MSA)
- Trial name
- PROSPECT-M (NCT02778607)
- Where
- United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University College, London
Optical Coherence Tomography, Optical Coherence Tomography Angiography
Relationship Between Alzheimer Disease and Diminution of the Three Macular Nervous Retinal Layers
Alzheimer disease is hard, long and expensive to diagnose. In order to help the clinician, a new biomarker in Alzheimer disease seems to be very useful.
- Conditions
- Optical Coherence Tomography, Optical Coherence Tomography Angiography, Retinal Thickening, Alzheimer Disease
- Trial name
- RETEVAL (NCT04794634)
- Testing
- Optical coherence tomography (OCT), Optical coherence tomograpohy angiography (OCTA)
- Where
- France
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Parkinson Disease, Prodromal Stage
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases.
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases
- Trial name
- ALPHA-FIT (NCT07324330)
- Testing
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Where
- Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.